Peptide Raw Powder Thymosin α1 Acetate / Desmopressin Acetate To Enhance Cell-Mediated Immunity Cas No.:62304-98-7
- Üretici firma: Dewael
- Ürün Analizi: 99%+
- Görünüm:Beyaz liyofilize toz
- Menşe Yeri: Çin
- Sertifikasyon: SGS,ISO9001,GMP
- Minimum Sipariş Miktarı: 100mi
- Paketleme Detayları: Gümrük geçişi garantili için gizli paketleme yolları
- Teslimat süresi: İçinde 12 ödemenizi aldıktan birkaç saat sonra
- Ödeme şartları: Batı Birliği, MoneyGram,Bitcoin,Banka transferi
- Nakliye: EMS,DHL,Fedex,GÜÇ KAYNAĞI,TNT ve benzeri.
- Politika: Yeniden Gönderim Politikası
- Tedarik yeteneği: 500-600Litre/ay
Peptide Raw Powder Thymosin α1 Acetate / Desmopressin Acetate To Enhance Cell-Mediated Immunity Cas No.:62304-98-7
Temel Bilgiler
Ürün adı: Desmopressin Asetat
Other Name: Thymosin Alpha 1 Acetate
CAS: 16789-98-3
takma ad: DDAVP, 1-Deamino-8-D-arginine-vasopressin diacetate, 1-(3-Mercaptopropionic acid)-8-D-arginine-vasopressin diacetate
CAS No.: 16789-98-3
Moleküler formül: C46H64N14O12S2
Moleküler ağırlık: 1189.32
Saflık (HPLC): 98.0%dk..
Görünüm: Beyaz toz
Tek Safsızlık (HPLC): 0.5%maksimum
Amino Asit Bileşimi: ± 10% of theoretical
Peptit İçeriği (N%): ≥ 80.0%
Water Content (Karl Fischer): ≤ 8.0%
Acetate Content (HPIC): ≤ 12.0%
MS (ESI): Tutarlı
Kütle Dengesi: 95.0~5,0
sınıf: Farmasötik Sınıf
Depolama: Kapalı, below 2 ~ 8º C preservation
kullanım: Desmopressin Acetate is used for nocturnal enuresis, coagulation zdisorders and diabetes insipidus.
Desmopressin (trade names: DDAVP, DesmoMelt, Minirin, Minirin Melt, Octim, Stimate) is a synthetic replacement for vasopressin, the hormone that reduces urine production. It may be taken nasally, intravenously, or as an oral or sublingual tablet. Physicians prescribe desmopressin most frequently for treatment of diabetes insipidus, bedwetting, or nocturia.
Thymosin α1 is a peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene. Thymosin Alpha-1 is a component of Thymosin Fraction 5 responsible for restoring immune function in animals lacking thymus glands. It was the original peptide synthesized from the Thymosin Fraction 5. Unlike β thymosins, which are genetically and chemically unrelated, Thymosin α1 is produced as a 28-amino acid peptide fragment from a longer, 113-amino acid precursor,prothymosin alpha. Research has shown it to enhance cell-mediated immunity in experimental animals and research subjects.
Thymosin Alpha-1 is being researched for the treatment of Hepatitis B and C, and it is also approved for inclusion with vaccines to boost the immune response in the treatment of other diseases.
Thymosin Alpha-1 is a component of Thymosin Fraction 5 responsible for restoring immune function in animals lacking thymus glands. It was the original peptide synthesized from the Thymosin Fraction 5. Unlike β Thymosins, which are genetically and chemically unrelated, Thymosin α 1 is produced as a 28-amino acid peptide fragment from a longer, 113-amino acid precursor, prothymosin alpha. Research has shown it to enhance cell-mediated immunity in experimental animals and research subjects…
Thymosin Alpha-1 is being researched for the treatment of Hepatitis B and C, and it is also approved for inclusion with vaccines to boost the immune response in the treatment of other diseases.
Exhibiting a variety of immune regulating properties, thymosin-alpha-1 induces differentiation of murine T-cell precursors and human thymocytes and the terminal differentiation of functionally immature cord blood lymphocytes and induces production of IL-2, high affinity IL-2 receptors, and B-cell growth factors by peripheral blood mononuclear cells. T-helper and cytotoxic/suppressor T-cell populations are targets of thymosin activity. Thymosin-alpha-1 has been shown to increase the efficiency of antigen presentation by macrophages and to be an endogenous modulator of alpha-thrombin activity.
Başvuru
Thymosin α 1 is now approved in 35 under developed or developing countries for the treatment of Hepatitis B and C, and it is also used to boost the immune response in the treatment of other diseases.
This product is mainly used for the treatment of chronic hepatitis B immune strengthening agent. Thymosin Alpha-1 is being researched for the treatment of Hepatitis
Thymosin α1 is now approved in 35 under developed or developing countries for the treatment of Hepatitis B and C, and it is also used to boost the immune response in the treatment of other diseases.
Exhibiting a variety of immune regulating properties, thymosin-alpha-1 induces differentiation of murine T-cell precursors and human thymocytes and the terminal differentiation of functionally immature cord blood lymphocytes and induces production of IL-2, high affinity IL-2 receptors, and B-cell growth factors by peripheral blood mononuclear cells. T-helper and cytotoxic/suppressor T-cell populations are targets of thymosin activity.
Thymosin-alpha-1 has been shown to increase the efficiency of antigen presentation by macrophages and to be an endogenous modulator of alpha-thrombin activity.
Şimdi kurun
Yorumlar
Henüz yorum yok.